keyword
https://read.qxmd.com/read/38462517/a-case-of-hereditary-coproporphyria-in-which-the-patient-s-course-improved-after-the-discontinuation-of-givosiran
#21
JOURNAL ARTICLE
Nobuaki Ozaki, Yuri Hayashi, Atsushi Kiyota
Hereditary coproporphyria (HCP) is caused by a partial deficiency of coproporphyrinogen oxidase during heme biosynthesis. Givosiran is approved for the treatment of acute hepatic porphyria. We herein report the case of a 47-year-old woman with HCP. Monthly givosiran administration improved her subjective symptoms and reduced her δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels to the normal range. However, givosiran was discontinued after six months due to a decreased renal function. The patient's ALA and PBG levels remained within the normal ranges, and her HCP-related symptoms resolved more than 2 years after the discontinuation of givosiran...
March 11, 2024: Internal Medicine
https://read.qxmd.com/read/38456621/liver-transplantation-and-primary-liver-cancer-in-porphyria
#22
REVIEW
Mattias Lissing, Bruce Wang, Staffan Wahlin
The porphyrias are a heterogeneous group of metabolic disorders that result from defects in heme synthesis. The metabolic defects are present in all cells, but symptoms are mainly cutaneous or related to neuropathy. The porphyrias are highly relevant to hepatologists since patients can present with symptoms and complications that require liver transplantation (LT), and some porphyrias are associated with a high risk for primary liver cancer (PLC). Among the cutaneous porphyrias, erythropoietic protoporphyria (EPP) can lead to cholestatic liver failure where LT cures the liver disease but not the porphyria...
March 8, 2024: Liver International: Official Journal of the International Association for the Study of the Liver
https://read.qxmd.com/read/38426312/health-benefits-of-combined-oral-contraceptives-a-narrative-review
#23
REVIEW
Herjan J T Coelingh Bennink, Femke A M van Gennip, Mireille G F Gerrits, Jan F M Egberts, Kristina Gemzell-Danielsson, Helena Kopp-Kallner
PURPOSE: This review presents an update of the non-contraceptive health benefits of the combined oral contraceptive pill. METHODS: We conducted a literature search for (review) articles that discussed the health benefits of combined oral contraceptives (COCs), in the period from 1980 to 2023. RESULTS: We identified 21 subjective and/or objective health benefits of COCs related to (i) the reproductive tract, (ii) non-gynaecological benign disorders and (iii) malignancies...
March 1, 2024: European Journal of Contraception & Reproductive Health Care
https://read.qxmd.com/read/38399495/use-of-optical-coherence-tomography-and-optical-coherence-tomography-angiography-in-the-diagnosis-and-follow-up-of-endogenous-candida-endophthalmitis-a-case-report
#24
Agnieszka Kubicka-Trząska, Dawid Bugara, Katarzyna Żuber-Łaskawiec, Weronika Pociej-Marciak, Anna Markiewicz, Bożena Romanowska-Dixon, Izabella Karska-Basta
Background: Endogenous Candida endophthalmitis (ECE) is a rare but sight-threatening disease. Patients with ECE present with various clinical signs and symptoms, which can complicate the diagnosis. The aim of this report was to demonstrate the outcomes of treatment and to diagnose macular complications caused by intraocular inflammation. Case presentation: A 41-year-old woman with a history of acute intermittent porphyria presented with a progressive vision loss in her left eye. Left-eye OCT revealed findings consistent with a fungal etiology, which was confirmed by the culture of swabs collected from a central vein catheter...
January 25, 2024: Medicina
https://read.qxmd.com/read/38375415/development-and-content-validation-of-novel-patient-reported-outcome-measures-to-assess-disease-severity-and-change-in-patients-with-erythropoietic-protoporphyria-the-epp-impact-questionnaire-epiq
#25
JOURNAL ARTICLE
Susan D Mathias, Laurie Burke, Hilary H Colwell, George Mensing, Will Savage, Hetanshi Naik
PURPOSE: Erythropoietic protoporphyria (EPP), a rare inherited disorder, presents in early childhood with severe, painful phototoxicity, with significant impacts on health-related quality of life (HRQoL). Previous studies have not captured all concepts important to patients. Therefore, this study sought to develop a novel, comprehensive, and content valid patient-reported outcome (PRO) measure to assess the efficacy of new therapies. PATIENTS AND METHODS: Qualitative interviews were conducted with EPP participants and clinical experts to obtain views on concepts relevant to patients...
2024: Patient related Outcome Measures
https://read.qxmd.com/read/38359998/rna-therapeutics-for-metabolic-disorders
#26
JOURNAL ARTICLE
Thuy-Duong Vu, Sheng-Che Lin, Chia-Ching Wu, Dinh-Toi Chu
The prevalence of metabolic disorders is increasing exponentially and has recently reached epidemic levels. Over the decades, a large number of therapeutic options have been proposed to manage these diseases but still show several limitations. In this circumstance, RNA therapeutics have rapidly emerged as a new hope for patients with metabolic diseases. 57 years have elapsed from the discovery of mRNA, a large number of RNA-based drug candidates have been evaluated for their therapeutic effectiveness and clinical safety under clinical studies...
2024: Progress in Molecular Biology and Translational Science
https://read.qxmd.com/read/38352109/dermatological-manifestations-in-patients-with-chronic-kidney-disease-a-review
#27
REVIEW
David Arriaga Escamilla, Alisha Lakhani, Sneha Antony, Karla N Salazar Villegas, Manasvi Gupta, Parameswaran Ramnath, María Isabel Murillo Pineda, Alexandra Bedor, Douglas Banegas, Ernesto Calderon Martinez
Chronic kidney disease (CKD) is a progressive disease and has multiple clinical manifestations; when CKD reaches the end stage, at least one cutaneous manifestation appears due to some increased toxin levels or a constant proinflammatory state. Nonspecific manifestations include pruritus, xerosis, pigmentation disorders, acquired ichthyosis, purpuric spots, and nail disorders. Some specific manifestations are bullous dermatoses, acquired perforating dermatoses (APD), eruptive xanthoma, access site infections, calcifying disorders, and nephrogenic systemic fibrosis (NSF)...
January 2024: Curēus
https://read.qxmd.com/read/38331857/efficacy-and-safety-of-deferoxamine-deferasirox-and-deferiprone-triple-iron-chelator-combination-therapy-for-transfusion-dependent-%C3%AE-thalassaemia-with-very-high-iron-overload-a-protocol-for-randomised-controlled-clinical-trial
#28
JOURNAL ARTICLE
Anuja Premawardhena, Chamodi Perera, Muditha Nayana Wijethilaka, Sakuni Keshani Wanasinghe, R H M G Rajakaruna, R A N K K Samarasinghe, Senani Williams, Sachith Mettananda
INTRODUCTION: Despite the improvement in medical management, many patients with transfusion-dependent β-thalassaemia die prematurely due to transfusion-related iron overload. As per the current guidelines, the optimal chelation of iron cannot be achieved in many patients, even with two iron chelators at their maximum therapeutic doses. Here, we evaluate the efficacy and safety of triple combination treatment with deferoxamine, deferasirox and deferiprone over dual combination of deferoxamine and deferasirox on iron chelation in patients with transfusion-dependent β-thalassaemia with very high iron overload...
February 8, 2024: BMJ Open
https://read.qxmd.com/read/38331236/nanoparticles-and-sirna-a-new-era-in-therapeutics
#29
JOURNAL ARTICLE
María Dolores Pérez-Carrión, Inmaculada Posadas, Valentín Ceña
Since its discovery in 1998, the use of small interfering RNA (siRNA) has been increasing in biomedical studies because of its ability to very selectively inhibit the expression of any target gene. Thus, siRNAs can be used to generate therapeutic compounds for different diseases, including those that are currently 'undruggable'. This has led siRNA-based therapeutic compounds to break into clinical settings, with them holding the promise to potentially revolutionise therapeutic approaches. To date, the United States Food and Drug Administration (FDA) have approved 5 compounds for treating different diseases including hypercholesterolemia, transthyretin-mediated amyloidosis (which leads to polyneuropathy), hepatic porphyria, and hyperoxaluria...
February 6, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38292155/congenital-erythropoietic-porphyria-five-years-observation-with-standard-treatment-a-case-report
#30
Marine Kamalyan, Mohammadmahdi Mohammadi
Porphyrias are a group of diseases characterized by a deficiency of enzymes in the haem biosynthetic pathway. Congenital Erythropoietic porphyria is a rare autosomal-recessive disorder lacking uroporphyrinogen III synthase. This inherited deficiency results in accumulating uroporphyrinogen I and coproporphyrinogen I in the bone marrow, skin, bones, and other tissues, ultimately excreted via urine and faeces. Clinical manifestations include severe photosensitivity on open body parts with blisters, scarring, hypertrichosis, and mutilations...
January 2024: Oxford Medical Case Reports
https://read.qxmd.com/read/38285491/insight-into-the-role-of-an-%C3%AE-helix-cluster-in-protoporphyrinogen-ix-oxidase
#31
JOURNAL ARTICLE
Baifan Wang, Yiban Wang, Zijuan Zhang, Xin Wen, Zhen Xi
Protoporphyrinogen IX oxidase (PPO) is the last common enzyme in chlorophyll and heme biosynthesis pathways. In humans, point mutations on PPO are responsible for the dominantly inherited disorder disease variegate porphyria (VP). It is found that several VP-causing mutation sites are located on an α-helix cluster (consisting of α-5, α-6, and α-7 helix, named the G169 helix cluster) of human PPO, although these mutation sites are outside the active site of the human PPO. In this work, we investigated the role of the G169 helix cluster via site-directed mutagenesis, enzymatic kinetics, and computational studies...
January 29, 2024: Biochemistry
https://read.qxmd.com/read/38276268/potential-biomarkers-for-the-earlier-diagnosis-of-kidney-and-liver-damage-in-acute-intermittent-porphyria
#32
JOURNAL ARTICLE
Elin Storjord, Staffan Wahlin, Bård Ove Karlsen, Randolf I Hardersen, Amy K Dickey, Judith K Ludviksen, Ole-Lars Brekke
Acute intermittent porphyria (AIP) is an inherited metabolic disorder associated with complications including kidney failure and hepatocellular carcinoma, probably caused by elevations in the porphyrin precursors porphobilinogen (PBG) and delta-aminolevulinic acid (ALA). This study explored differences in modern biomarkers for renal and hepatic damage between AIP patients and controls. Urine PBG testing, kidney injury panels, and liver injury panels, including both routine and modern biomarkers, were performed on plasma and urine samples from AIP cases and matched controls (50 and 48 matched pairs, respectively)...
December 21, 2023: Life
https://read.qxmd.com/read/38267243/effects-of-ferric-derisomaltose-on-postoperative-anaemia-in-adult-spinal-deformity-surgery-a-study-protocol-for-a-randomised-controlled-trial
#33
JOURNAL ARTICLE
Jing Zhan, Yang Jiao, Weiyun Chen, Yuguang Huang, Jianxiong Shen
INTRODUCTION: Postoperative anaemia is prevalent in adult spinal deformity (ASD) surgery in association with unfavourable outcomes. Ferric derisomaltose, a novel iron supplement, offers a promising solution in rapidly treating postoperative anaemia. However, the clinical evidence of its effect on patients receiving spinal surgery remains inadequate. This randomised controlled trial aims to evaluate the safety and efficacy of ferric derisomaltose on postoperative anaemia in ASD patients...
January 24, 2024: BMJ Open
https://read.qxmd.com/read/38255745/severe-perinatal-presentations-of-g%C3%A3-nther-s-disease-series-of-20-cases-and-perspectives
#34
JOURNAL ARTICLE
Claire Goudet, Cécile Ged, Audrey Petit, Chloe Desage, Perrine Mahe, Aicha Salhi, Ines Harzallah, Jean-Marc Blouin, Patrick Mercie, Caroline Schmitt, Antoine Poli, Laurent Gouya, Vincent Barlogis, Emmanuel Richard
(1) Background: Congenital erythropoietic porphyria (CEP), named Günther's disease, is a rare recessive type of porphyria, resulting from deficient uroporphyrinogen III synthase (UROS), the fourth enzyme of heme biosynthesis. The phenotype ranges from extremely severe perinatal onset, with life-threatening hemolytic anaemia, to mild or moderate cutaneous involvement in late-onset forms. This work reviewed the perinatal CEP cases recorded in France in order to analyse their various presentations and evolution...
January 17, 2024: Life
https://read.qxmd.com/read/38254627/cimetidine-does-not-inhibit-5-aminolevulinic-acid-synthase-or-heme-oxygenase-activity-implications-for-treatment-of-acute-intermittent-porphyria-and-erythropoietic-protoporphyria
#35
JOURNAL ARTICLE
Makiko Yasuda, Sangmi Lee, Lin Gan, Hector A Bergonia, Robert J Desnick, John D Phillips
Acute intermittent porphyria (AIP) is characterized by acute neurovisceral attacks that are precipitated by the induction of hepatic 5-aminolevulinic acid synthase 1 (ALAS1). In erythropoietic protoporphyria (EPP), sun exposure leads to skin photosensitivity due to the overproduction of photoreactive porphyrins in bone marrow erythroid cells, where heme synthesis is primarily driven by the ALAS2 isozyme. Cimetidine has been suggested to be effective for the treatment of both AIP and EPP based on limited case reports...
December 24, 2023: Biomolecules
https://read.qxmd.com/read/38230223/paraneoplastic-cutaneous-manifestations-of-hepatocellular-carcinoma-a-systematic-review-and-meta-analysis
#36
REVIEW
Laith Al-Showbaki, Ahmad A Toubasi, Dunia Z Jaber, Mohammad Al Shdifat, Noor Al-Maani, Omar Qudah, Feras Fararjeh, Eitan Amir
Background: There remains a scarcity of published data on the clinical significance of paraneoplastic cutaneous manifestations in hepatocellular carcinoma (HCC). Method: A systematic search of MEDLINE was performed in December 2022. Inclusion criteria comprised studies reporting on patients with HCC, who had paraneoplastic cutaneous manifestations. Outcomes of interests comprise survival and response to cancer-directed and/or skin directed therapy. Results: A total of 48 studies comprising 60 HCC patients were included in the analysis...
2024: Journal of Cancer
https://read.qxmd.com/read/38205357/obstacles-to-early-diagnosis-of-acute-hepatic-porphyria-current-perspectives-on-improving-early-diagnosis-and-clinical-management
#37
REVIEW
Manish Thapar, Akash Singh, Kevin M Robinson, Herbert L Bonkovsky
Porphyrias are, for the most part, inherited disorders of the heme biosynthetic pathway which lead to accumulation of specific intermediates responsible for most of the symptoms and signs of biochemically active disease. Acute hepatic porphyrias usually come to clinical attention primarily in women in their reproductive years who present with episodic, severe, generalized abdominal pain. Such acute attacks may also be associated with tachycardia, systemic arterial hypertension, hyponatremia, recent history of dark reddish to brownish urine, and anxiety, delirium, and sensory or motor neuropathies...
2024: Clinical and Experimental Gastroenterology
https://read.qxmd.com/read/38201016/german-porphyria-registry-poreger-background-and-setup
#38
JOURNAL ARTICLE
Lea Gerischer, Mona Mainert, Nils Wohmann, Ilja Kubisch, Ulrich Stölzel, Thomas Stauch, Sabine von Wegerer, Fabian Braun, Christina Weiler-Normann, Sabine Blaschke, Jorge Frank, Rajan Somasundaram, Eva Diehl-Wiesenecker
Porphyrias, as most rare diseases, are characterized by complexity and scarcity of knowledge. A national registry in one of the largest European populations that prospectively collects longitudinal clinical and laboratory data are an important and effective tool to close this gap. The German Porphyria Registry (PoReGer) was founded by four centers with longstanding expertise in the field of porphyrias and rare diseases (Charité-Universitätsmedizin Berlin, Porphyria Center Saxony Chemnitz, University Medical Center Hamburg-Eppendorf, University Medical Center Göttingen) and the German reference laboratory for porphyria, and is supported by the largest German porphyria patient organization...
January 3, 2024: Healthcare (Basel, Switzerland)
https://read.qxmd.com/read/38151366/porphyria-cutanea-tarda-in-a-human-immunodeficiency-virus-positive-patient
#39
JOURNAL ARTICLE
Andrés Grau-Echevarría, Carolina Labrandero-Hoyos, Rodrigo Peñuelas-Leal, Daniel Blaya-Imbernón, Malena Finello, Gemma María Pérez-Pastor, Pablo Hernández-Bel, Amparo Pérez-Ferriols
No abstract text is available yet for this article.
December 26, 2023: Medicina Clínica
https://read.qxmd.com/read/38148975/clinical-feature-and-genetic-analysis-of-hmbs-gene-in-chinese-patients-with-acute-intermittent-porphyria-a-systematic-review
#40
Yi Ren, Shuang Li, Jia-Jia Lei, Ru Li, Bai-Xue Dong, Jing Yang
Background: Early detection and diagnosis are important crucial to prevent life-threatening acute attacks in patients with acute intermittent porphyria (AIP). We aim to provide comprehensive data on the clinical and hydroxymethylbilane synthase (HMBS) gene variant characteristics and genotype-phenotype association of Chinese patients with AIP in order to improve clinicians' knowledge of AIP and reduce misdiagnosis and mistaken treatment. Methods: We searched the literature on Chinese patients with AIP in PubMed, Web of Science, Wiley Online Library, ScienceDirect and Chinese literature databases up to August 2023 in our analysis to explore the clinical and HMBS gene variant characteristics of Chinese patients with AIP...
2023: Frontiers in Genetics
keyword
keyword
14287
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.